geranylgeranyl pyrophosphate

Geranylgeranyl pyrophosphate, a key metabolite in protein geranylgeranylation, serves as the universal precursor for diterpenoids, such as Paclitaxel. Its role in cancer research stems from this critical function.

Geranylgeranyl pyrophosphate tetrabutylammonium(1：2) is one of the endogenous cholesterol and intermediates produced by the mevalerate pathway. Geranylgeranyl pyrophosphate tetrabutylammonium(1：2) is the common precursor of diterpenoids, for example, Paclitaxel. It can be used for cancer research.

(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl dihydrogen diphosphate,tetrabutylammonium(1:1.5) is a common precursor of taxadiene such as Paclitaxel.

Geranylgeranyl pyrophosphate is an intermediate in the HMG-CoA reductase pathway derived directly from farnesyl pyrophosphate and used in the biosynthesis of terpenes and terpenoids.[1] It is also serves as a substrate in the prenylation of a variety of critical intracellular proteins including small GTPases.[2] This post-translational modification is necessary for correct localization of proteins to intracellular membranes for proper functionality and has become a focus of anticancer drug discovery.[3][4]

Digeranyl bisphosphonate (DGBP) is a potent geranylgeranyl pyrophosphate (GGPP) synthase inhibitor that inhibits geranyl pyrophosphorylation of Rac1.Digeranyl bisphosphonate induces autophagy but not apoptosis.

Geranyl pyrophosphate is an intermediate in the mevalonate pathway. It is formed from dimethylallyl pyrophosphate and isopentenyl pyrophosphate by geranyl pyrophosphate synthase. Geranyl pyrophosphate is used in the biosynthesis of farnesyl pyrophosphate , geranylgeranyl pyrophosphate , cholesterol, terpenes, and terpenoids.

hGGPPS-IN-2 is an analogue of C-2 substituted thienopyrimidinyl bisphosphonates (C2-ThP-BPs) and is a potent inhibitor of human geranylgeranyl pyrophosphate synthase (hGGPPS). hGGPPS-IN-2 targets multiple myeloma (MM) cells, induces selective apoptosis, and shows anti-myeloma effects in vivo. It has shown anti-myeloma effects in vivo.

Compound 13h (hGGPPS-IN-3) is a potent inhibitor of human geranylgeranyl pyrophosphate synthase (hGGPPS), characterized as a C-2-substituted thienopyrimidine-based bisphosphonate analogue (C2-ThP-BPs). It selectively induces apoptosis in multiple myeloma (MM) cells and demonstrates antimyeloma activity in vivo [1].